Evidence map›Paper›PMID 41136833›Full record

ReviewAdvances in experimental medicine and biology2025

Emerging Ethical Challenges in Manufacturing of Cell-Based Medicines.

Lieke van Kempen, Katherine Lieschke, Nienke de Graeff, Martine C de Vries, Megan Munsie

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lieke van KempenDepartment of Medical Ethics and Health Law, Leiden University Medical Center, Leiden, The Netherlands.
Katherine LieschkeStem Cell Biology Theme, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Nienke de GraeffDepartment of Medical Ethics and Health Law, Leiden University Medical Center, Leiden, The Netherlands.
Martine C de VriesDepartment of Medical Ethics and Health Law, Leiden University Medical Center, Leiden, The Netherlands.
Megan MunsieStem Cell Biology Theme, Murdoch Children's Research Institute, Parkville, VIC, Australia. megan.munsie@unimelb.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter explores new ethical issues raised by recent developments in the manufacture of cell-based medicines and revisit ethical issues that havepreviously been acknowledged in the context of contemporary technologies. We follow the translational pathway of cell-based medicines and address ethical challenges along the way. Our journey encompasses a thorough examination of five central themes: (1) the complexities in the informed consent process, (2) the intricacies of cell banking and distributing, (3) the crucial role of governance and oversight, (4) the significance of representation, diversity, and equity in translational research and (5) the responsibility to enable access to effective cell-based products. This discussion also underlines the responsibility of the scientific community to be aware of, and where possible, address these challenges. By describing the ethical questions parallel to the translational process, this chapter provides a streamlined overview of the ethical challenges of cell therapy manufacturing.

Indexed as

Cell- and Tissue-Based TherapyTranslational Research, BiomedicalHumansInformed ConsentAccessBiobankingCell-based medicinesEthicsGovernanceInformed consent

Identifiers

PMID41136833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.